News
05-30-2012, 09:30 PM
Exelixis, Inc. today announced the initiation of COMET-1, a phase 3 pivotal trial of cabozantinib in men with metastatic castration-resistant prostate cancer.
More... (http://www.news-medical.net/news/20120531/Exelixis-commences-cabozantinib-phase-3-pivotal-trial-in-mCRPC.aspx)
More... (http://www.news-medical.net/news/20120531/Exelixis-commences-cabozantinib-phase-3-pivotal-trial-in-mCRPC.aspx)